

What is claimed is

1 1. A humanized immunoglobulin, which is a humanized
2 version of the mouse AF2 immunoglobulin having a light chain
3 variable region designated SEQ ID No:2 and a heavy chain
4 variable region designated SEQ ID No:4, the humanized
5 immunoglobulin comprising humanized heavy and light chains,
6 provided that position 11 of the humanized heavy chain
7 variable region framework is occupied by the amino acid
8 present in the equivalent position of the mouse AF2 heavy
9 chain variable region framework.

1 2. The humanized immunoglobulin of claim 1,
2 comprising CDRs from the mouse AF2 immunoglobulin and heavy
3 and light chain variable region frameworks from the human EU
4 immunoglobulin.

1 3. The humanized immunoglobulin of claim 2, further
2 provided that position H38 is occupied by the amino acid
3 present in the equivalent position of the mouse AF2 heavy
4 chain variable region framework.

1 4. The humanized immunoglobulin of claim 2, further
2 provided that positions H11, H27, H28, H30, H38, H48, H67,
3 H68, H70, H72, H74, H93, H95, H98, H107, H108, H109, H111 are
4 occupied by the amino acid present in the equivalent position
5 of the mouse AF2 heavy chain, positions L48, and L70 are
6 occupied by the amino acid present in the equivalent position
7 of the mouse AF2 light chain, and position L63 is occupied by
8 the amino acid present in the equivalent position of a
9 consensus sequence of light chains of human immunoglobulins.

1 5. The humanized immunoglobulin of claim 1 that
2 specifically binds to human γ -IFN with an affinity constant
3 within four-fold of the affinity of the mouse AF2 antibody.

1 6. The humanized immunoglobulin of claim 1 that
2 specifically binds to γ -IFN comprising a humanized mature light

3 chain having at least 90% sequence identity to the mature
4 light chain of SEQ ID No:6, and a humanized mature heavy chain
5 having at least 90% sequence identity to the mature heavy
6 chain of SEQ ID No:8.

1 7. The humanized immunoglobulin according to claim 1
2 that comprises two light chain/heavy chain dimers.

1 8. The humanized immunoglobulin of claim 1 that is of
2 IgG1 isotype.

1 9. The humanized immunoglobulin according to claim 1,
2 which is purified to at least 95% homogeneity.

1 10. A humanized immunoglobulin comprising a mature
2 heavy chain variable region designated SEQ ID No:6 and a
3 mature light chain variable region designated SEQ ID No:8.

1 11. A pharmaceutical composition comprising a
2 humanized immunoglobulin of claim 1 or 10 and a
3 pharmaceutically acceptable carrier.

1 12. A method of treating a patient suffering from a
2 harmful immune response, comprising administering a
3 therapeutically effective dosage of the pharmaceutical
4 composition of claim 1 or 10.

1 13. The method of claim 12, wherein the patient is
2 suffering from an autoimmune disease.